We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
Read MoreHide Full Article
The most recent trading session ended with Rockwell Medical (RMTI - Free Report) standing at $1.34, reflecting a -0.74% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.6%. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.92%.
Shares of the maker of products used in the treatment of kidney disease and anemia have depreciated by 6.25% over the course of the past month, underperforming the Medical sector's gain of 4.52% and the S&P 500's gain of 3.56%.
Market participants will be closely following the financial results of Rockwell Medical in its upcoming release. The company plans to announce its earnings on March 21, 2024. The company's upcoming EPS is projected at -$0.08, signifying a 60% increase compared to the same quarter of the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Rockwell Medical. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Rockwell Medical is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
The most recent trading session ended with Rockwell Medical (RMTI - Free Report) standing at $1.34, reflecting a -0.74% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.6%. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.92%.
Shares of the maker of products used in the treatment of kidney disease and anemia have depreciated by 6.25% over the course of the past month, underperforming the Medical sector's gain of 4.52% and the S&P 500's gain of 3.56%.
Market participants will be closely following the financial results of Rockwell Medical in its upcoming release. The company plans to announce its earnings on March 21, 2024. The company's upcoming EPS is projected at -$0.08, signifying a 60% increase compared to the same quarter of the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Rockwell Medical. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Rockwell Medical is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.